VCYT Q2 2020 Earnings — Veracyte, Inc. Revenue & Financial Results | Market Cap Arena

VCYTVeracyte, Inc.

$3B

Q2 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$21M-31.3% YoY

Gross Profit

$13M63.0% margin

Operating Income

-$11M-53.4% margin

Net Income

-$11M-53.3% margin

EPS (Diluted)

$-0.22

QoQ Revenue Growth

-33.5%

Cash Flow

Operating Cash Flow

-$8M

Free Cash Flow

-$9M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$257M

Total Liabilities

$31M

Stockholders' Equity

$226M

Cash & Equivalents

$147M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$21M	$30M	-31.3%
Gross Profit	$13M	$21M	-38.9%
Operating Income	-$11M	-$3M	-256.5%
Net Income	-$11M	-$2M	-342.1%

Revenue Segments

Biopharmaceutical

$4M69%

Product

$2M31%